Efficient Inhibition of Intimal Hyperplasia by Adenovirus-Mediated Inducible Nitric Oxide Synthase Gene Transfer to Rats and Pigs in Vivo
- 1 September 1998
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 187 (3) , 295-306
- https://doi.org/10.1016/s1072-7515(98)00163-x
Abstract
Background: Inadequate nitric oxide (NO) availability may underlie vascular smooth muscle overgrowth that contributes to vascular occlusive diseases including atherosclerosis and restenosis. NO possesses a number of properties that should inhibit this hyperplastic healing response, such as promoting reendothelialization, preventing platelet and leukocyte adherence, and inhibiting cellular proliferation. Study Design: We proposed that shortterm but sustained increases in NO synthesis achieved with inducible NO synthase (iNOS) gene transfer at sites of vascular injury would prevent intimal hyperplasia. We constructed an adenoviral vector, AdiNOS, carrying the human iNOS cDNA and used it to express iNOS at sites of arterial injury in vivo. Results: AdiNOS-treated cultured vascular smooth muscle cells produced up to 100-fold more NO than control cells. In vivo iNOS gene transfer, using low concentrations of AdiNOS (2 × 106 plaque forming units [PFU]/rat) to injured rat carotid arteries, resulted in a near complete (>95%) reduction in neointima formation even when followed longterm out to 6 weeks post-injury. This protective effect was reversed by the continuous administration of an iNOS selective inhibitor L-N6-(1-iminoethyl)-lysine. However, iNOS gene transfer did not lead to regression of preestablished neointimal lesions. In an animal model more relevant to human vascular healing, iNOS gene transfer (5 × 108 PFU/pig) to injured porcine iliac arteries in vivo was also efficacious, reducing intimal hyperplasia by 51.8%. Conclusions: These results indicate that shortterm overexpression of the iNOS gene initiated at the time of vascular injury is an effective method of locally increasing NO levels to prevent intimal hyperplasia.Keywords
This publication has 36 references indexed in Scilit:
- Vascular inducible nitric oxide synthase gene therapy: Requirement for guanosine triphosphate cyclohydrolase ISurgery, 1996
- Molecular Therapies for Vascular DiseasesScience, 1996
- Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.Journal of Clinical Investigation, 1995
- Redox signaling: Nitrosylation and related target interactions of nitric oxideCell, 1994
- Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial InjuryScience, 1994
- Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury.The Journal of Experimental Medicine, 1994
- Peripheral and central vascular smooth muscle cells from rat lung exhibit different cytoskeletal protein profiles but similar growth factor requirementsJournal of Cellular Physiology, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.Journal of Clinical Investigation, 1989
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977